During the last session, Brickell Biotech Inc. (NASDAQ:BBI)’s traded shares were 2.59 million, with the beta value of the company hitting 0.11. At the end of the trading day, the stock’s price was $0.21, reflecting an intraday gain of 3.45% or $0.01. The 52-week high for the BBI share is $1.04, that puts it down -395.24 from that peak though still a striking 4.76% gain since the share price plummeted to a 52-week low of $0.20. The company’s market capitalization is $25.53M, and the average trade volume was 5.45 million shares over the past three months.
Brickell Biotech Inc. (BBI) received a consensus recommendation of a Buy from analysts. That translates to a mean rating of 1.50. BBI has a Sell rating from 0 analyst(s) out of 4 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 4 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -$0.06.
Brickell Biotech Inc. (NASDAQ:BBI) trade information
Brickell Biotech Inc. (BBI) registered a 3.45% upside in the last session and has traded in the red over the past 5 sessions. The stock spiked 3.45% in intraday trading to $0.21 this Thursday, 05/12/22, hitting a weekly high. The stock’s 5-day price performance is -13.39%, and it has moved by -15.38% in 30 days. Based on these gigs, the overall price performance for the year is -75.66%.
The consensus price target of analysts on Wall Street is $2.50, which implies an increase of 91.6% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $2.00 and $4.00 respectively. As a result, BBI is trading at a discount of -1804.76% off the target high and -852.38% off the low.
Brickell Biotech Inc. (BBI) estimates and forecasts
Statistics show that Brickell Biotech Inc. has outperformed its competitors in share price, compared to the industry in which it operates. Brickell Biotech Inc. (BBI) shares have gone down -41.22% during the last six months, with a year-to-date growth rate more than the industry average at 59.18% against 9.70. Yet analysts are ramping up their growth forecast for the fiscal year 2022. Revenue is predicted to grow 60.00% this quarter and then jump 68.80% in the quarter after that. In the rating firms’ projections, revenue will increase 350.50% compared to the previous financial year.
Revenue for the current quarter is expected to be $140k as predicted by 4 analyst(s). Meanwhile, a consensus of 4 analyst(s) estimates revenue growth to $920k by the end of Jun 2022. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled $17k and $151k respectively. In this case, analysts expect current quarter sales to grow by 723.50% and then jump by 509.30% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 39.90%. While earnings are projected to return 42.40% in 2022.
Brickell Biotech Inc. is due to release its next quarterly earnings between August 10 and August 15. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Brickell Biotech Inc. (NASDAQ:BBI)’s Major holders
Brickell Biotech Inc. insiders own 1.31% of total outstanding shares while institutional holders control 18.31%, with the float percentage being 18.56%. Renaissance Technologies, LLC is the largest shareholder of the company, while 39 institutions own stock in it. As of Dec 30, 2021, the company held over 3.04 million shares (or 2.54% of all shares), a total value of $0.69 million in shares.
The next largest institutional holding, with 2.71 million shares, is of Vanguard Group, Inc. (The)’s that is approximately 2.27% of outstanding shares. At the market price on Dec 30, 2021, these shares were valued at $0.62 million.
Also, the Mutual Funds coming in first place with the largest holdings of Brickell Biotech Inc. (BBI) shares are Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund. Data provided on Dec 30, 2021 indicates that Vanguard Total Stock Market Index Fund owns about 1.85 million shares. This amounts to just over 1.55 percent of the company’s overall shares, with a $0.42 million market value. The same data shows that the other fund manager holds slightly less at 0.85 million, or about 0.71% of the stock, which is worth about $0.19 million.